APAX Apax Global Alpha

Hardman & Co Q&A on Apax Global Alpha (APAX): Confirming strong underlying competitive advantages

Hardman & Co Research
Hardman & Co Q&A on Apax Global Alpha (APAX): Confirming strong underlying competitive advantages

12-Oct-2023 / 14:15 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

Analyst interview | Investment Companies

Q&A on Apax Global Alpha (APAX) | Confirming strong underlying competitive advantages

 

Apax Global Alpha is the topic of conversation when Mark Thomas joins DirectorsTalk.

 

In this interview Mark delves into the key theme of his recent report entitled ''. Mark also discusses AGA's strengths, such as its impressive revenue and EBITDA growth, conservative accounting practices, and stable returns from its debt portfolio.

 

Apax Global Alpha (LON:APAX) is a closed-ended investment company that invests in a portfolio of private equity funds advised by Apax, and a focused portfolio of debt and equity.


Listen to the interview:

 

If you are interested in meeting the company, you can register your interest
 

To contact us:

Hardman & Co
1 Frederick's Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Analyst:

Mark Thomas



 

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1747833  12-Oct-2023 

fncls.ssp?fn=show_t_gif&application_id=1747833&application_name=news&site_id=research_pool
EN
12/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apax Global Alpha

Brian Moretta ... (+3)
  • Brian Moretta
  • Jason Streets
  • Mark Thomas

Hardman & Co Monthly: May 2025

Feature article: Attractive asset managers - Radical derating presumes things only get worse The UK asset management sector has been significantly derated over the past couple of years. It has faced the dual problem of a shift towards passives and to private assets and away from traditional listed equities and bonds. However, the sector’s assets haven’t collapsed; its margins have proved relatively robust and its profits fairly stable, even against all the rising costs. The clear implication, ...

Mark Thomas
  • Mark Thomas

Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today

AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (no longer a core sector), and one portfolio company in particular, meant the strong average investee company EBITDA growth did not fuel NAV growth. However, the detail in the results bodes well, with i) investee companies deliveri...

 PRESS RELEASE

Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and...

Hardman & Co Research Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today 02-Apr-2025 / 11:39 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today   AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (...

Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: April 2025

Feature article: 2024 pharma statistics An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched ant...

Apax Global Alpha Limited: 1 director

A director at Apax Global Alpha Limited bought 15,000 shares at 134p and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch